Search results
Showing 7486 to 7500 of 7672 results
Over 700 people a year could benefit from a new lung cancer drug
An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
New tests could spare people with early breast cancer from unnecessary chemotherapy
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
Home testing devices could increase the number of people diagnosed with sleep apnoea
Five home-testing devices to diagnose a silent sleep condition harming the health of an estimated 2.5 million adults have been recommended by NICE in draft guidance.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.
170,000 people in England to have further treatment choice for preventing migraine attacks
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
Public consultation on our new approach to prioritising guidance now open
The consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.